| Description |
SRX3207 is an orally active and first-in-class dual Syk/PI3K inhibitor. SRX3207 possesses anti-tumor activity[1].
|
| Related Catalog |
|
| In Vitro |
SRX3207 (10 μmol/L) is able to block p-AKT at concentration[1]. SRX3207 has sufficient solubility in water (43 μmol/L)[1].
|
| In Vivo |
SRX3207 (10 mg/kg, orally) increases antitumor immune response[1]. Animal Model: LLC or B16 or B16-OVA or CT26 (1 × 105) cells were injected subcutaneously into syngeneic mice[1]. Dosage: 10 mg/kg. Administration: Orally, starting from day 10 when tumors reached 100 mm3 until tumors were harvested on day 21. Result: Blocked phosphorylation of Syk at 348 site and Y525/526 site. Blocked immunosuppressive MΦ polarization. Blocked tumor growth and increased survival effectively.
|
| References |
[1]. Shweta Joshi, et al. Macrophage Syk–PI3Kγ Inhibits Antitumor Immunity: SRX3207, a Novel Dual Syk–PI3K Inhibitory Chemotype Relieves Tumor Immunosuppression. Molecular Cancer Therapeutics. 2020.
|
